AstraZeneca Remuneration Report 2016

Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful). Manifest comment Shareholders may wish to note that this resolution previously recorded a high level of dissent with 39.31%. The targets used to determine the directors' annual bonus in respect of the year under review have not been fully disclosed. The level of the upper bonus cap for certain of the executive directors may be of concern. The aggregate of all long-term incentive awards made to Soriot represents 499% of salary (on a market value basis, based on maximum possible vesting). The aggregate maximum potential incentive pay for the CEO in respect of the year exceeds 668% of salary. There are no disclosures to indicate that the Remuneration Committee considers ESG issues when

...

Not a member? Join today

Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:

Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities

Join now

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.